Summary & Overview
HCPCS J7681: Terbutaline Sulfate Inhalation Solution, Compounded, per mg
HCPCS Level II code J7681 represents terbutaline sulfate inhalation solution as a compounded, unit-dose product billed per milligram and delivered through durable medical equipment. This code captures the dispensing and billing pathway for a bronchodilator formulation used in inhalation therapy when the product is compounded and provided in unit doses for administration via DME. Nationally, accurate coding for compounded inhalation solutions affects coverage determinations, DME billing workflows, and claims processing consistency across commercial and public payers.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, common billing modifiers, typical sites of service, and clinical context relevant to inhaled bronchodilator therapy delivered through DME. The publication outlines benchmark metrics and policy considerations for billing and reimbursement of compounded inhalation products, and highlights operational implications for providers and billing teams.
Content is presented to support coding accuracy and administrative clarity for stakeholders managing DME-based inhalation medication claims. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J7681 denotes terbutaline sulfate, inhalation solution, compounded product, billed per milligram in unit dose form, and administered through durable medical equipment (DME). The service type is inhalation medication administration via DME, and the typical site of service is home or outpatient settings where DME is used to deliver inhaled therapy. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with acute bronchospasm due to asthma or chronic obstructive pulmonary disease (COPD) who requires short-acting beta-2 agonist therapy delivered via a nebulizer and durable medical equipment (DME) in the home or outpatient setting. The compounded J7681 product — terbutaline sulfate inhalation solution in unit-dose form, billed per milligram — is prepared by a pharmacy or compounding service and supplied for use with a patient’s DME nebulizer. Clinical workflow: a prescribing clinician documents the indication and dosage, the pharmacy compounds and labels unit-dose vials, the DME supplier provides compatible nebulizer equipment and education on administration, and nursing or respiratory therapy may assist with initial dosing and monitoring. Typical administration scenarios include acute exacerbation management in an emergency department observation unit, transition-of-care prescriptions at hospital discharge for home nebulizer use, or outpatient infusion/respiratory therapy clinics providing inhalation treatments under supervision.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no modifier applies and billing requires the primary HCPCS only |